Chemical Structure (Granisetron 01)
Granisetron Hydrochloride Tablet
Product Images NDC 51991-735
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Granisetron Hydrochloride (NDC 51991-735). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Breckenridge Pharmaceutical, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Principal Display Panel (2 Tablet Blister Pack Carton)
Each tablet of Granisetron Hydrochloride contains 1.12 mg of granisetron hydrochloride USP equivalent to granisetron, 1 mg. It is a medication used to prevent nausea and vomiting caused by cancer chemotherapy and radiation therapy. The suggested dosage is 2 mg once daily or 1 mg twice daily. For chemotherapy administration, two tablets of 1 mg each are taken up to 1 hour before chemotherapy in the 2mg once daily regimen. In the 1 mg twice daily regimen, the first 1 mg tablet is given 1 hour before chemotherapy, and the second one 12 hours after the first. Two 1mg tablets of Granisetron are taken within 1 hour of radiation for radiation therapy. This drug should be stored between 20°C to 26°C, protected from light, and kept in its carton until the time of use. The manufacturing details and dosage information can be found in the accompanying prescribing information.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
